Clarus Therapeutics Holdings, Inc. (CRXWQ) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Clarus Therapeutics Holdings, Inc. (CRXWQ) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Die Aktie erzielt 68/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 16. März 2026Clarus Therapeutics Holdings, Inc. (CRXWQ) Gesundheitswesen & Pipeline-Uebersicht
Clarus Therapeutics Holdings, Inc., operating in the pharmaceuticals sector, focuses on men's health with its primary product, JATENZO, an oral testosterone replacement therapy. The company navigated a challenging market landscape, ultimately facing financial difficulties and trading on the OTC market under the ticker CRXWQ.
Investmentthese
Investing in Clarus Therapeutics Holdings, Inc. (CRXWQ) presents significant risks due to its OTC market listing and past financial challenges. The company's primary asset, JATENZO, faces competition and reimbursement hurdles. A potential investment hinges on a successful restructuring or acquisition that unlocks value from its existing assets. Investors should closely monitor the company's financial disclosures, regulatory developments, and any potential strategic partnerships or acquisitions. Given the company's history and current OTC status, a highly speculative approach is warranted.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Gross Margin of 80.5% indicates strong potential profitability if sales volume can be increased.
- Negative Profit Margin of -404.9% highlights significant operational inefficiencies and financial distress.
- JATENZO was the primary product, an oral softgel for testosterone replacement therapy.
- The company faced challenges in securing reimbursement from payers for JATENZO.
- Clarus Therapeutics Holdings, Inc. trades on the OTC market under the ticker CRXWQ.
Staerken
- Proprietary oral formulation of testosterone (JATENZO).
- Focus on the men's health market.
- Established relationships with some healthcare providers.
Schwaechen
- Financial difficulties and OTC market listing.
- Negative profit margin.
- Limited market share.
- Competition from established players and generic alternatives.
Risiken
- Ongoing: The company's OTC listing reflects significant financial distress and operational challenges.
- Potential: Limited liquidity in the OTC market can lead to price volatility and difficulty in trading shares.
- Potential: The lack of financial disclosure increases the risk of information asymmetry and potential fraud.
- Potential: Competition from established players and generic alternatives could further erode the company's market share.
- Potential: Regulatory hurdles and reimbursement challenges could hinder the commercialization of its products.
Wachstumschancen
- Potential Acquisition: Clarus Therapeutics' assets, including JATENZO and related intellectual property, could be acquired by a larger pharmaceutical company seeking to expand its men's health portfolio. The timeline for a potential acquisition is uncertain, but it represents a potential value realization opportunity for current shareholders. The market size for men's health therapies is substantial, making Clarus' assets potentially attractive to strategic acquirers.
- Restructuring and Turnaround: A successful restructuring of Clarus Therapeutics could involve streamlining operations, reducing debt, and focusing on core assets. If the company can achieve operational efficiencies and improve its financial position, it may be able to regain investor confidence and increase its market value. The timeline for a successful turnaround is uncertain and depends on the company's ability to execute its restructuring plan.
- New Product Development: Clarus Therapeutics could explore the development of new products or formulations in the men's health space. This could involve leveraging its existing expertise and infrastructure to create innovative therapies that address unmet needs. The timeline for new product development is typically lengthy and requires significant investment in research and development. However, successful new product launches could drive long-term growth and profitability.
- Strategic Partnerships: Clarus Therapeutics could form strategic partnerships with other pharmaceutical companies or healthcare providers to expand its market reach and access new distribution channels. These partnerships could involve co-marketing agreements, licensing deals, or joint ventures. Strategic partnerships can provide access to new markets and resources, accelerating growth and reducing risk. The timeline for forming strategic partnerships is variable and depends on the availability of suitable partners.
- International Expansion: Clarus Therapeutics could explore opportunities to expand its operations into international markets. This could involve seeking regulatory approvals for JATENZO in other countries and establishing distribution networks to reach new customers. International expansion can significantly increase the company's addressable market and drive revenue growth. However, it also requires significant investment and expertise in navigating foreign regulatory environments and cultural differences.
Chancen
- Potential acquisition by a larger pharmaceutical company.
- Successful restructuring and turnaround.
- New product development.
- Strategic partnerships.
- International expansion.
Risiken
- Competition from established players and generic alternatives.
- Regulatory hurdles.
- Reimbursement challenges.
- Product liability risks.
- Economic downturn.
Wettbewerbsvorteile
- Proprietary formulation of JATENZO (oral softgel testosterone).
- Established relationships with healthcare providers.
- Intellectual property protection for its products.
- Brand recognition in the men's health market.
Ueber CRXWQ
Clarus Therapeutics Holdings, Inc. was a pharmaceutical company dedicated to the development and commercialization of therapies for men's health. The company's flagship product was JATENZO, an oral softgel formulation of testosterone indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). JATENZO aimed to provide a convenient and effective treatment option for men experiencing low testosterone levels. Founded with the goal of addressing unmet needs in men's health, Clarus Therapeutics sought to differentiate itself through innovative formulations and targeted marketing efforts. The company faced significant challenges in the competitive pharmaceutical market, including navigating regulatory hurdles, securing reimbursement from payers, and effectively marketing its product to healthcare providers and patients. Despite its efforts, Clarus Therapeutics encountered financial difficulties, leading to its current status on the OTC market under the ticker CRXWQ.
Was das Unternehmen tut
- Developed and commercialized JATENZO, an oral testosterone replacement therapy.
- Focused on addressing unmet needs in men's health.
- Sought regulatory approvals for its products.
- Marketed its products to healthcare providers and patients.
- Navigated the competitive pharmaceutical market.
- Aimed to provide convenient and effective treatment options for men experiencing low testosterone levels.
Geschaeftsmodell
- Develop and commercialize pharmaceutical products.
- Generate revenue through sales of prescription medications.
- Market products to healthcare providers and patients.
- Seek reimbursement from payers for its products.
Branchenkontext
Clarus Therapeutics Holdings, Inc. operated within the competitive pharmaceutical industry, specifically targeting the men's health market. The testosterone replacement therapy market is characterized by established players and generic alternatives. Companies in this space face challenges related to regulatory approvals, marketing, and reimbursement. Market trends include a growing awareness of men's health issues and an increasing demand for convenient and effective treatment options. Clarus Therapeutics aimed to capture a share of this market with JATENZO, but faced competition and financial hurdles.
Wichtige Kunden
- Adult males diagnosed with hypogonadism (low testosterone).
- Healthcare providers who prescribe testosterone replacement therapy.
- Pharmacies that dispense prescription medications.
- Payers (insurance companies and government healthcare programs) that reimburse for prescription medications.
Finanzdaten
Chart & Info
Clarus Therapeutics Holdings, Inc. (CRXWQ) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer CRXWQ verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CRXWQ.
Kursziele
Wall-Street-Kurszielanalyse fuer CRXWQ.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von CRXWQ auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
CRXWQ OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Clarus Therapeutics Holdings, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors and may be subject to greater risks. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and less scrutiny, potentially leading to increased volatility and information asymmetry.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure increases information asymmetry and the risk of fraud.
- Low trading volume and wide bid-ask spreads can lead to significant price volatility.
- The OTC Other tier carries a higher risk of shell company activity and manipulation.
- The company's financial difficulties and past bankruptcy raise concerns about its long-term viability.
- Lack of regulatory oversight increases the potential for mismanagement and corporate governance issues.
- Verify the company's registration and legal standing with the relevant authorities.
- Attempt to obtain and review any available financial statements, even if limited.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC Other securities.
- Consult with a qualified financial advisor before making any investment decisions.
- Be extremely cautious of any unsolicited investment offers or promotional materials.
- The company previously traded on a major exchange before moving to the OTC market.
- JATENZO was an FDA-approved product, indicating some level of regulatory compliance.
- The company has a history of operations, even if currently distressed.
Clarus Therapeutics Holdings, Inc. Aktie: Wichtige Fragen beantwortet
What are the key factors to evaluate for CRXWQ?
Clarus Therapeutics Holdings, Inc. (CRXWQ) currently holds an AI score of 68/100, indicating moderate score. Key strength: Proprietary oral formulation of testosterone (JATENZO).. Primary risk to monitor: Ongoing: The company's OTC listing reflects significant financial distress and operational challenges.. This is not financial advice.
How frequently does CRXWQ data refresh on this page?
CRXWQ prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CRXWQ's recent stock price performance?
Recent price movement in Clarus Therapeutics Holdings, Inc. (CRXWQ) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary oral formulation of testosterone (JATENZO).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CRXWQ overvalued or undervalued right now?
Determining whether Clarus Therapeutics Holdings, Inc. (CRXWQ) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CRXWQ?
Before investing in Clarus Therapeutics Holdings, Inc. (CRXWQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CRXWQ to a portfolio?
Potential reasons to consider Clarus Therapeutics Holdings, Inc. (CRXWQ) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary oral formulation of testosterone (JATENZO).. Additionally: Focus on the men's health market.. The AI-driven MoonshotScore of 68/100 reflects solid quantitative fundamentals. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of CRXWQ?
Yes, most major brokerages offer fractional shares of Clarus Therapeutics Holdings, Inc. (CRXWQ) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CRXWQ's earnings and financial reports?
Clarus Therapeutics Holdings, Inc. (CRXWQ) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CRXWQ earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is limited due to the company's OTC status and lack of recent filings.
- AI analysis is pending and may provide further insights.